Platinum Based Doublet | List of Frontiers open access articles

Case Report

Published on 13 Apr 2026

Surgical management of metastatic squamous cell carcinoma of the bladder: a case report and review of the literature

in Genitourinary Oncology

Michael Schwartz
Caitlin Hartman
Greta McClintock
Sarah Caulfield
Jaishree Jagirdar
Lara Harik
David Berkowitz
Felix Fernandez
Sonal Oza
Vikram Narayan

Frontiers in Oncology

doi 10.3389/fonc.2026.1806454

322 views

Original Research

Published on 11 Nov 2025

Efficacy and prognostic analysis of chemo-immunotherapy after TKI resistance in EGFR-mutant non-small cell lung cancer with TP53 or KRAS co-mutations

in Cancer Immunity and Immunotherapy

Yuhui Nie
Chen Song
Kun Wu
Mingxin Yu
Jia Hu
Shuzhen Liu
Fu Hui

Frontiers in Immunology

doi 10.3389/fimmu.2025.1684089

2,482 views
1 citation

Original Research

Published on 02 May 2025

Cost-effectiveness of atezolizumab versus chemotherapy in patients with non-small-cell lung cancer ineligible for platinum-based doublet chemotherapy

in Health Economics

Qiuji Wu
Yi Qin
Qiu Li

Frontiers in Public Health

doi 10.3389/fpubh.2025.1349645

4,041 views
2 citations

Original Research

Published on 30 Mar 2026

Influence of chemotherapy intensity on opportunistic fungal infection risk in non-small cell lung carcinoma: a retrospective study

in Pulmonary Medicine

Fang Zheng
Wenli Li
Fei Zhao
Zhenzhen Zhu
Weiyang Wang
Qinghai You

Frontiers in Medicine

doi 10.3389/fmed.2026.1800575

350 views

Original Research

Published on 11 Feb 2021

nab-Paclitaxel Plus Durvalumab in Patients With Previously Treated Advanced Stage Non-small Cell Lung Cancer (ABOUND.2L+)

in Thoracic Oncology

Daniel Morgensztern
Manuel Cobo Dols
Santiago Ponce Aix
Pieter E. Postmus
Jaafar Bennouna
Jürgen R. Fischer
Oscar Juan-Vidal
David J. Stewart
Andrea Ardizzoni
Rafia Bhore

Frontiers in Oncology

doi 10.3389/fonc.2020.569715

6,537 views
4 citations

Original Research

Published on 07 May 2021

Pemetrexed-Platinum With or Without Bevacizumab for Chinese Chemo-Naive Advanced Lung Adenocarcinoma Patients: A Real-World Study

in Pharmacology of Anti-Cancer Drugs

Xin Li
Jie Huang
Yao Qiu
Qianyun Zhang
Shaoyu Yang
Kan Wu
Jiaoli Wang
Limin Wang
Jian Ye
Shenglin Ma

Frontiers in Pharmacology

doi 10.3389/fphar.2021.649222

4,865 views
4 citations

Original Research

Published on 24 Nov 2025

Neoadjuvant chemotherapy versus surgery alone in locally advanced esophageal squamous cell carcinoma: a propensity-matched real-world study

in Gastrointestinal Cancers: Gastric and Esophageal Cancers

Yuchen Wang
Zhifeng Yue
Zhifeng Li
Jin Yang
Jifang Yao
Junfeng Liu

Frontiers in Oncology

doi 10.3389/fonc.2025.1691998

975 views

Systematic Review

Published on 28 Jul 2025

Cost-effectiveness of chemotherapy for advanced and recurrent cervical cancer: a systematic review

in Health System Economics and Financing

Katsuaki Inami

Frontiers in Health Services

doi 10.3389/frhs.2025.1616223

4,720 views
1 citation

Review

Published on 19 Sep 2017

Radiotherapy for Oligometastatic Lung Cancer

in Radiation Oncology

Derek P. Bergsma
Joseph K. Salama
Deepinder P. Singh
Steven J. Chmura
Michael T. Milano

Frontiers in Oncology

doi 10.3389/fonc.2017.00210

14,019 views
57 citations

Case Report

Published on 11 Jan 2024

Sinus metastasis of lung adenocarcinoma: a case report

in Pulmonary Medicine

Mingyuan Xu
Qi Sun
Xin Lv
Fangjun Chen
Shu Su
Lifeng Wang

Frontiers in Medicine

doi 10.3389/fmed.2023.1323222

3,252 views
2 citations

Systematic Review

Published on 13 Apr 2021

First-Generation EGFR-TKI Plus Chemotherapy Versus EGFR-TKI Alone as First-Line Treatment in Advanced NSCLC With EGFR Activating Mutation: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

in Thoracic Oncology

Qiang Wu
Wuxia Luo
Wen Li
Ting Wang
Lin Huang
Feng Xu

Frontiers in Oncology

doi 10.3389/fonc.2021.598265

10,639 views
43 citations

Original Research

Published on 21 Oct 2024

A real-world retrospective study to assess efficacy and safety of alectinib as adjuvant therapy in IB-IIIB NSCLC patients harboring ALK rearrangement

in Thoracic Oncology

Zeng-Hao Chang
Teng-Fei Zhu
Wei Ou
Hao Jiang
Si-Yu Wang

Frontiers in Oncology

doi 10.3389/fonc.2024.1422035

4,237 views
5 citations

Articles

Surgical management of metastatic squamous cell carcinoma of the bladder: a case report and review of the literature

Efficacy and prognostic analysis of chemo-immunotherapy after TKI resistance in EGFR-mutant non-small cell lung cancer with TP53 or KRAS co-mutations

Cost-effectiveness of atezolizumab versus chemotherapy in patients with non-small-cell lung cancer ineligible for platinum-based doublet chemotherapy

Influence of chemotherapy intensity on opportunistic fungal infection risk in non-small cell lung carcinoma: a retrospective study

nab-Paclitaxel Plus Durvalumab in Patients With Previously Treated Advanced Stage Non-small Cell Lung Cancer (ABOUND.2L+)

Pemetrexed-Platinum With or Without Bevacizumab for Chinese Chemo-Naive Advanced Lung Adenocarcinoma Patients: A Real-World Study

Neoadjuvant chemotherapy versus surgery alone in locally advanced esophageal squamous cell carcinoma: a propensity-matched real-world study

Cost-effectiveness of chemotherapy for advanced and recurrent cervical cancer: a systematic review

Radiotherapy for Oligometastatic Lung Cancer

Sinus metastasis of lung adenocarcinoma: a case report

First-Generation EGFR-TKI Plus Chemotherapy Versus EGFR-TKI Alone as First-Line Treatment in Advanced NSCLC With EGFR Activating Mutation: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

A real-world retrospective study to assess efficacy and safety of alectinib as adjuvant therapy in IB-IIIB NSCLC patients harboring ALK rearrangement